Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Business Wire
Bipolar Depression: How do we treat it?
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Small Clinical Trials Lead To Big Results
Rx Product News: April 2023
Proper Résumés - Résumés that stand out and breakthrough applicant tracking systems. | Facebook
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha
Sage advice: psychiatric drug development is tough | Evaluate
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
sage-10k_20181231.htm
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Rx Product News: April 2023
Sage surges after depression drug gets rapid path to approval - PMLiVE
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
sage-10k_20191231.htm
